Atara Biotherapeutics, Inc. (ATRA) stock
ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.70−0.23 (-2.90%)
Close on Nov 13, 2026Market cap $77.29MP/E –Yield –
Atara Biotherapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Atara Biotherapeutics's operating margin for the twelve months ending Sep 30, 2026 was -343.6%. For fiscal 2025 it was 29.7%, against -64.7% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 29.7% | +94.4 |
| FY2024 | Dec 31, 2024 | -64.7% | +3154.8 |
| FY2023 | Dec 31, 2023 | -3219.5% | −2778.2 |
| FY2022 | Dec 31, 2022 | -441.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -242.6% | −139.1 |
| Q2 FY2026 | Jun 30, 2026 | -749.2% | −767.4 |
| Q1 FY2026 | Mar 31, 2026 | -652.9% | −692.4 |
| Q4 FY2025 | Dec 31, 2025 | -160.7% | −123.4 |
| Q3 FY2025 | Sep 30, 2025 | -103.5% | −49.4 |
| Q2 FY2025 | Jun 30, 2025 | 18.2% | +81.8 |
| Q1 FY2025 | Mar 31, 2025 | 39.5% | +153.8 |
| Q4 FY2024 | Dec 31, 2024 | -37.3% | +1372.9 |
| Q3 FY2024 | Sep 30, 2024 | -54.1% | +3201.8 |
| Q2 FY2024 | Jun 30, 2024 | -63.7% | +7398.6 |
| Q1 FY2024 | Mar 31, 2024 | -114.2% | +6004.7 |
| Q4 FY2023 | Dec 31, 2023 | -1410.2% | +32770.3 |
| Q3 FY2023 | Sep 30, 2023 | -3255.9% | −1358.2 |
| Q2 FY2023 | Jun 30, 2023 | -7462.3% | −7400.0 |
| Q1 FY2023 | Mar 31, 2023 | -6118.9% | −4912.7 |
| Q4 FY2022 | Dec 31, 2022 | -34180.5% | – |
| Q3 FY2022 | Sep 30, 2022 | -1897.8% | – |
| Q2 FY2022 | Jun 30, 2022 | -62.3% | – |
| Q1 FY2022 | Mar 31, 2022 | -1206.2% | – |
See a number that looks wrong?